Back to Search Start Over

Bioenergetic modulators hamper cancer cell viability and enhance response to chemotherapy

Authors :
Sara Granja
Odília Queirós
Diana Tavares-Valente
Fátima Baltazar
Universidade do Minho
Source :
Journal of Cellular and Molecular Medicine, Repositório Científico de Acesso Aberto de Portugal, Repositório Científico de Acesso Aberto de Portugal (RCAAP), instacron:RCAAP
Publication Year :
2018
Publisher :
Wiley, 2018.

Abstract

Gliomas are characterized by a marked glycolytic metabolism with a consequent production of massive amounts of lactate, even in the presence of normal levels of oxygen, associated to increased invasion capacity and to higher resistance to conventional treatment. This work aimed to understand how the metabolic modulation can influence tumour aggressive features and its potential to be used as complementary therapy. We assessed the effect of bioenergetic modulators (BMs) targeting different metabolic pathways in glioma cell characteristics. The in vivo effect of BMs was evaluated using the chicken chorioallantoic membrane model. Additionally, the effect of pre-treatment with BMs in the response to the antitumour drug temozolomide (TMZ) was analysed in vitro. Cell treatment with the BMs induced a decrease in cell viability and in migratory/invasion abilities, as well as modifications in metabolic parameters (glucose, lactate and ATP) and increased the cytotoxicity of the conventional drug TMZ. Furthermore, all BMs decreased the tumour growth and the number of blood vessels in an in vivo model. Our results demonstrate that metabolic modulation has the potential to be used as therapy to decrease the aggressiveness of the tumours or to be combined with conventional drugs used in glioma treatment.<br />Project NORTE‐01‐0145‐FEDER‐000013, supported by the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal Partnership Agreement, through the European Regional Development Fund (FEDER), and through the Competitiveness Factors Operational Programme (COMPETE) and by National funds, through the Foundation for Science and Technology (FCT), under the scope of the project POCI‐01‐0145‐FEDER‐007038. This work was also supported by an internal CESPU project 02‐GBMC‐CICS‐2011 MetabRes_CESPU_2017. DT‐V received a fellowship from FCT (ref. SFRH/BD/103025/2014). SG received a fellowship from FCT (ref. SFRH/BPD/117858/2016)<br />info:eu-repo/semantics/publishedVersion

Details

ISSN :
15824934 and 15821838
Volume :
22
Database :
OpenAIRE
Journal :
Journal of Cellular and Molecular Medicine
Accession number :
edsair.doi.dedup.....b3ec09dd17a15393f45463315299caa4
Full Text :
https://doi.org/10.1111/jcmm.13642